These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35853823)

  • 1. [Postoperative radiotherapy with cetuximab for head and neck squamous cell carcinoma patients at high risk of recurrence not eligible for cisplatin: A single-center experience and literature review].
    Marques O; Brenet E; Gaultier V; Marchand-Crety C
    Cancer Radiother; 2023 Feb; 27(1):17-22. PubMed ID: 35853823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
    Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
    J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.
    Saraswathula A; Chen MM; Colevas AD; Divi V
    JAMA Otolaryngol Head Neck Surg; 2019 Dec; 145(12):1160-1167. PubMed ID: 31621810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.
    Magnes T; Wagner SM; Melchardt T; Weiss L; Rinnerthaler G; Huemer F; Kopp M; Gampenrieder SP; Mayrbäurl B; Füreder T; Lenger D; Andel J; Egle A; Greil R
    Wien Klin Wochenschr; 2021 Nov; 133(21-22):1131-1136. PubMed ID: 34528125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
    Hitt R; Mesía R; Lozano A; Iglesias Docampo L; Grau JJ; Taberna M; Rubió-Casadevall J; Martínez-Trufero J; Morillo EDB; García Girón C; Vázquez Estévez S; Cirauqui B; Cruz-Hernández JJ
    Oral Oncol; 2022 Nov; 134():106087. PubMed ID: 36126605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
    Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
    JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
    Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy plus cetuximab or cisplatin in head and neck squamous cell carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.
    Li Y; Yang C; Gan Y; Lu F; Qin Y
    Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):11-22. PubMed ID: 35986743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
    Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
    Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
    Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.
    Awan MJ; Nedzi L; Wang D; Tumati V; Sumer B; Xie XJ; Smith I; Truelson J; Hughes R; Myers LL; Lavertu P; Wong S; Yao M
    Ann Oncol; 2018 Apr; 29(4):998-1003. PubMed ID: 29346519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between weekly cisplatin-enhanced radiotherapy and cetuximab-enhanced radiotherapy in locally advanced head and neck cancer: first retrospective study in Asian population.
    Rawat S; Ahlawat P; Kakria A; Kumar G; Rangaraju RR; Puri A; Pal M; Chauhan D; Devnani B; Chadha P
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):195-203. PubMed ID: 27813277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radiotherapy for head and neck squamous cell carcinoma: State of the art and future directions].
    Schick U; Huguet F; Pointreau Y; Pradier O
    Cancer Radiother; 2017 Oct; 21(6-7):498-504. PubMed ID: 28864046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.
    Merlano M; Russi E; Benasso M; Corvò R; Colantonio I; Vigna-Taglianti R; Vigo V; Bacigalupo A; Numico G; Crosetto N; Gasco M; Lo Nigro C; Vitiello R; Violante S; Garrone O
    Ann Oncol; 2011 Mar; 22(3):712-717. PubMed ID: 20810547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
    Adkins D; Ley J; Trinkaus K; Thorstad W; Lewis J; Wildes T; Siegel BA; Dehdashti F; Gay H; Mehan P; Nussenbaum B
    Cancer; 2013 Feb; 119(4):766-73. PubMed ID: 22991252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study.
    Addeo R; Caraglia M; Vincenzi B; Luce A; Montella L; Mastella A; Mazzone S; Ricciardiello F; Carraturo M; Del Prete S; Sperlongano P
    Chemotherapy; 2019; 64(1):48-56. PubMed ID: 31242489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.